Weekly
The Weekly Peptide Brief
Every Monday: new trial readouts, regulatory changes across the US and abroad, and independent safety or purity findings. Each item links to its primary source. No protocols, no vendor promotions.
Recent issues covered
- 2026-08-10
What the FDA's 503A Category 2 List Actually Means for Peptide Access
- 2026-07-28
Retatrutide Phase III Data Sets a New Ceiling for Weight-Loss Pharmacology
- 2026-07-15
Independent Testing Keeps Finding the Same Problem in Grey-Market Peptide Vials
- 2026-06-30
Australia Remains the Strictest Peptide Jurisdiction in the Developed World
- 2026-06-12
The Lean-Mass Question Is Now the Most Important Open Problem in Incretin Therapy